The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Vaccine for Non-infectious Meningitis-Global Market Insights and Sales Trends 2025
Synopsis
Meningococcal conjugate vaccine is used to prevent infection caused by meningococcal bacteria.
The global Vaccine for Non-infectious Meningitis market size is expected to reach US$ 2 million by 2029, growing at a CAGR of 12.0% from 2023 to 2029. The market is mainly driven by the significant applications of Vaccine for Non-infectious Meningitis in various end use industries. The expanding demands from the Meningitis, Septicemia and Others,, are propelling Vaccine for Non-infectious Meningitis market. Polysaccharide Vaccines, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Conjugate Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Vaccine for Non-infectious Meningitis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Vaccine for Non-infectious Meningitis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Vaccine for Non-infectious Meningitis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Vaccine for Non-infectious Meningitis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Vaccine for Non-infectious Meningitis covered in this report include Serum Institute, Sanofi SA, Pfizer, Nuron Biotech and JN-International Medical, etc.
The global Vaccine for Non-infectious Meningitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Serum Institute
Sanofi SA
Pfizer
Nuron Biotech
JN-International Medical
Global Vaccine for Non-infectious Meningitis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Vaccine for Non-infectious Meningitis market, Segment by Type:
Polysaccharide Vaccines
Conjugate Vaccines
Combination Vaccines
Men B Vaccines
Global Vaccine for Non-infectious Meningitis market, by Application
Meningitis
Septicemia
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Vaccine for Non-infectious Meningitis manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Vaccine for Non-infectious Meningitis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Meningococcal conjugate vaccine is used to prevent infection caused by meningococcal bacteria.
The global Vaccine for Non-infectious Meningitis market size is expected to reach US$ 2 million by 2029, growing at a CAGR of 12.0% from 2023 to 2029. The market is mainly driven by the significant applications of Vaccine for Non-infectious Meningitis in various end use industries. The expanding demands from the Meningitis, Septicemia and Others,, are propelling Vaccine for Non-infectious Meningitis market. Polysaccharide Vaccines, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Conjugate Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Vaccine for Non-infectious Meningitis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Vaccine for Non-infectious Meningitis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Vaccine for Non-infectious Meningitis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Vaccine for Non-infectious Meningitis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Vaccine for Non-infectious Meningitis covered in this report include Serum Institute, Sanofi SA, Pfizer, Nuron Biotech and JN-International Medical, etc.
The global Vaccine for Non-infectious Meningitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Serum Institute
Sanofi SA
Pfizer
Nuron Biotech
JN-International Medical
Global Vaccine for Non-infectious Meningitis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Vaccine for Non-infectious Meningitis market, Segment by Type:
Polysaccharide Vaccines
Conjugate Vaccines
Combination Vaccines
Men B Vaccines
Global Vaccine for Non-infectious Meningitis market, by Application
Meningitis
Septicemia
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Vaccine for Non-infectious Meningitis manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Vaccine for Non-infectious Meningitis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Vaccine for Non-infectious Meningitis Market Overview
1.1 Vaccine for Non-infectious Meningitis Product Overview
1.2 Vaccine for Non-infectious Meningitis Market Segment by Type
1.2.1 Polysaccharide Vaccines
1.2.2 Conjugate Vaccines
1.2.3 Combination Vaccines
1.2.4 Men B Vaccines
1.3 Global Vaccine for Non-infectious Meningitis Market Size by Type
1.3.1 Global Vaccine for Non-infectious Meningitis Market Size Overview by Type (2018-2029)
1.3.2 Global Vaccine for Non-infectious Meningitis Historic Market Size Review by Type (2018-2023)
1.3.3 Global Vaccine for Non-infectious Meningitis Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Vaccine for Non-infectious Meningitis Sales Breakdown by Type (2018-2023)
1.4.2 Europe Vaccine for Non-infectious Meningitis Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Vaccine for Non-infectious Meningitis Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Vaccine for Non-infectious Meningitis Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Vaccine for Non-infectious Meningitis Sales Breakdown by Type (2018-2023)
2 Global Vaccine for Non-infectious Meningitis Market Competition by Company
2.1 Global Top Players by Vaccine for Non-infectious Meningitis Sales (2018-2023)
2.2 Global Top Players by Vaccine for Non-infectious Meningitis Revenue (2018-2023)
2.3 Global Top Players by Vaccine for Non-infectious Meningitis Price (2018-2023)
2.4 Global Top Manufacturers Vaccine for Non-infectious Meningitis Manufacturing Base Distribution, Sales Area, Product Type
2.5 Vaccine for Non-infectious Meningitis Market Competitive Situation and Trends
2.5.1 Vaccine for Non-infectious Meningitis Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Vaccine for Non-infectious Meningitis Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccine for Non-infectious Meningitis as of 2022)
2.7 Date of Key Manufacturers Enter into Vaccine for Non-infectious Meningitis Market
2.8 Key Manufacturers Vaccine for Non-infectious Meningitis Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Vaccine for Non-infectious Meningitis Status and Outlook by Region
3.1 Global Vaccine for Non-infectious Meningitis Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Vaccine for Non-infectious Meningitis Historic Market Size by Region
3.2.1 Global Vaccine for Non-infectious Meningitis Sales in Volume by Region (2018-2023)
3.2.2 Global Vaccine for Non-infectious Meningitis Sales in Value by Region (2018-2023)
3.2.3 Global Vaccine for Non-infectious Meningitis Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Vaccine for Non-infectious Meningitis Forecasted Market Size by Region
3.3.1 Global Vaccine for Non-infectious Meningitis Sales in Volume by Region (2024-2029)
3.3.2 Global Vaccine for Non-infectious Meningitis Sales in Value by Region (2024-2029)
3.3.3 Global Vaccine for Non-infectious Meningitis Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Vaccine for Non-infectious Meningitis by Application
4.1 Vaccine for Non-infectious Meningitis Market Segment by Application
4.1.1 Meningitis
4.1.2 Septicemia
4.1.3 Others
4.2 Global Vaccine for Non-infectious Meningitis Market Size by Application
4.2.1 Global Vaccine for Non-infectious Meningitis Market Size Overview by Application (2018-2029)
4.2.2 Global Vaccine for Non-infectious Meningitis Historic Market Size Review by Application (2018-2023)
4.2.3 Global Vaccine for Non-infectious Meningitis Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Vaccine for Non-infectious Meningitis Sales Breakdown by Application (2018-2023)
4.3.2 Europe Vaccine for Non-infectious Meningitis Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Vaccine for Non-infectious Meningitis Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Vaccine for Non-infectious Meningitis Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Vaccine for Non-infectious Meningitis Sales Breakdown by Application (2018-2023)
5 North America Vaccine for Non-infectious Meningitis by Country
5.1 North America Vaccine for Non-infectious Meningitis Historic Market Size by Country
5.1.1 North America Vaccine for Non-infectious Meningitis Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Vaccine for Non-infectious Meningitis Sales in Volume by Country (2018-2023)
5.1.3 North America Vaccine for Non-infectious Meningitis Sales in Value by Country (2018-2023)
5.2 North America Vaccine for Non-infectious Meningitis Forecasted Market Size by Country
5.2.1 North America Vaccine for Non-infectious Meningitis Sales in Volume by Country (2024-2029)
5.2.2 North America Vaccine for Non-infectious Meningitis Sales in Value by Country (2024-2029)
6 Europe Vaccine for Non-infectious Meningitis by Country
6.1 Europe Vaccine for Non-infectious Meningitis Historic Market Size by Country
6.1.1 Europe Vaccine for Non-infectious Meningitis Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Vaccine for Non-infectious Meningitis Sales in Volume by Country (2018-2023)
6.1.3 Europe Vaccine for Non-infectious Meningitis Sales in Value by Country (2018-2023)
6.2 Europe Vaccine for Non-infectious Meningitis Forecasted Market Size by Country
6.2.1 Europe Vaccine for Non-infectious Meningitis Sales in Volume by Country (2024-2029)
6.2.2 Europe Vaccine for Non-infectious Meningitis Sales in Value by Country (2024-2029)
7 Asia-Pacific Vaccine for Non-infectious Meningitis by Region
7.1 Asia-Pacific Vaccine for Non-infectious Meningitis Historic Market Size by Region
7.1.1 Asia-Pacific Vaccine for Non-infectious Meningitis Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Vaccine for Non-infectious Meningitis Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Vaccine for Non-infectious Meningitis Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Vaccine for Non-infectious Meningitis Forecasted Market Size by Region
7.2.1 Asia-Pacific Vaccine for Non-infectious Meningitis Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Vaccine for Non-infectious Meningitis Sales in Value by Region (2024-2029)
8 Latin America Vaccine for Non-infectious Meningitis by Country
8.1 Latin America Vaccine for Non-infectious Meningitis Historic Market Size by Country
8.1.1 Latin America Vaccine for Non-infectious Meningitis Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Vaccine for Non-infectious Meningitis Sales in Volume by Country (2018-2023)
8.1.3 Latin America Vaccine for Non-infectious Meningitis Sales in Value by Country (2018-2023)
8.2 Latin America Vaccine for Non-infectious Meningitis Forecasted Market Size by Country
8.2.1 Latin America Vaccine for Non-infectious Meningitis Sales in Volume by Country (2024-2029)
8.2.2 Latin America Vaccine for Non-infectious Meningitis Sales in Value by Country (2024-2029)
9 Middle East and Africa Vaccine for Non-infectious Meningitis by Country
9.1 Middle East and Africa Vaccine for Non-infectious Meningitis Historic Market Size by Country
9.1.1 Middle East and Africa Vaccine for Non-infectious Meningitis Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Vaccine for Non-infectious Meningitis Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Vaccine for Non-infectious Meningitis Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Vaccine for Non-infectious Meningitis Forecasted Market Size by Country
9.2.1 Middle East and Africa Vaccine for Non-infectious Meningitis Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Vaccine for Non-infectious Meningitis Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Serum Institute
10.1.1 Serum Institute Company Information
10.1.2 Serum Institute Introduction and Business Overview
10.1.3 Serum Institute Vaccine for Non-infectious Meningitis Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Serum Institute Vaccine for Non-infectious Meningitis Products Offered
10.1.5 Serum Institute Recent Development
10.2 Sanofi SA
10.2.1 Sanofi SA Company Information
10.2.2 Sanofi SA Introduction and Business Overview
10.2.3 Sanofi SA Vaccine for Non-infectious Meningitis Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Sanofi SA Vaccine for Non-infectious Meningitis Products Offered
10.2.5 Sanofi SA Recent Development
10.3 Pfizer
10.3.1 Pfizer Company Information
10.3.2 Pfizer Introduction and Business Overview
10.3.3 Pfizer Vaccine for Non-infectious Meningitis Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Pfizer Vaccine for Non-infectious Meningitis Products Offered
10.3.5 Pfizer Recent Development
10.4 Nuron Biotech
10.4.1 Nuron Biotech Company Information
10.4.2 Nuron Biotech Introduction and Business Overview
10.4.3 Nuron Biotech Vaccine for Non-infectious Meningitis Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Nuron Biotech Vaccine for Non-infectious Meningitis Products Offered
10.4.5 Nuron Biotech Recent Development
10.5 JN-International Medical
10.5.1 JN-International Medical Company Information
10.5.2 JN-International Medical Introduction and Business Overview
10.5.3 JN-International Medical Vaccine for Non-infectious Meningitis Sales, Revenue and Gross Margin (2018-2023)
10.5.4 JN-International Medical Vaccine for Non-infectious Meningitis Products Offered
10.5.5 JN-International Medical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Vaccine for Non-infectious Meningitis Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Vaccine for Non-infectious Meningitis Industrial Chain Analysis
11.4 Vaccine for Non-infectious Meningitis Market Dynamics
11.4.1 Vaccine for Non-infectious Meningitis Industry Trends
11.4.2 Vaccine for Non-infectious Meningitis Market Drivers
11.4.3 Vaccine for Non-infectious Meningitis Market Challenges
11.4.4 Vaccine for Non-infectious Meningitis Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Vaccine for Non-infectious Meningitis Distributors
12.3 Vaccine for Non-infectious Meningitis Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
